Table 1 Level of evidence (LoE), Quality of Study and demographics of patients included in the 12 studies
From: Stem cells for the treatment of early to moderate osteoarthritis of the knee: a systematic review
Author | Study Type | LoE | Quality of study | N patients (Knees) | Lost FU | MSCs | Control Group | Gender (M/F) | Mean Age (years) | BMI (kg/m2) | Mean FU (months) | FU (range) | Study Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Garay-Mendoza 2017 [7] | PCS | 3 | 14/16 | 30 (30) | 4 | BMAC | Acetaminophen (31) | 7/23 | 55.7 | 29.5 | 6 | n.a | |
Tsubosaka 2020 [21] | PCoS | 3 | 13/16 | 60 (60) | 3 | SVF | n.a | 69.4 | 25.1 | 13.7 | 11.7–15.7 | September 2017 – March 2018 | |
Wells 2020 [24] | PCoS | 3 | 13/16 | 10 (13) | BMAC | 4/6 | 55.3 | n.a | 12 | April 2017—December 2018 | |||
Varady 2020 [22] | PCoS | 3 | 12/16 | 17 (17) | BMAC | 7/10 | 54 | n.a | 12 | March 2018—March 2019 | |||
Estrada 2020 [3] | PCS | 3 | 13/16 | 33 (33) | SVF | PRP (29) | n.a | 54.7 | 25.5 | 12 | March 2012—July 2019 | ||
27 (27) | BMAC | n.a | 54.7 | 25.5 | 12 | ||||||||
Garza 2020 [8] | RCT | 2 | 7/8 | 13 (13) | SVF | Placebo | 4/9 | 60.5 | 27.6 | 12 | July 2016 – September 2017 | ||
13 (13) | SVF DD | Placebo | 7/6 | 59.5 | 28.8 | 12 | |||||||
Kaszynski 2022 [10] | RCT | 2 | 6/8 | 20 (20) | SVF | PRP (20) Control (20) | 55 | 27 | 12 | n.a | |||
Yokota 2022 [27] | POC | 3 | 14/16 | 38 (69) | SVF | Culture ASC (72) | 7/31 | 73 | 25 | 24 | November 2016 – April 2017 | ||
Zhang 2022 [28] (Stem Cell Research & Therapy) | RCT | 2 | 8/8 | 56 (56) | 5 | SVF | HA (64) | 14/42 | 54 | 23.7 | 60 | May 2013—July 2015 | |
Zhang 2022 [29] (BioMed Research International) | RCT | 2 | 6/8 | 50 (53) | SVF | HA (51) | 18/29 | 50.8 | 22.7 | 12 | January 2018—May 2021 | ||
Altetto 2022 [1] | PCoS | 3 | 12/16 | 123 (123) | SVF | 57/66 | 57 | 27 | 6 | June 2019—November 2020 | |||
Anz 2022 [2] | RCT | 3 | 5/8 | 49 (49) | 4 | BMAC | PRP (39) | 27/18 | 55.8 | 27.7 | 24 | n.a |